Spots Global Cancer Trial Database for A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
Official Title: A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Study ID: NCT02391480
Study Description
Brief Summary: This is a Phase 1, first-in-human, dose escalation study in participants with advanced solid tumors to determine the pharmacokinetics, maximum tolerated dose and the recommended Phase 2 dose of ABBV-075 at different monotherapy dosing schedules. In addition the study will evaluate the safety. tolerability and the pharmacokinetics of ABBV-075 monotherapy or combination therapy in disease specific expansion cohorts.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Scottsdale Healthcare /ID# 132963, Scottsdale, Arizona, United States
City of Hope /ID# 154053, Duarte, California, United States
UC Davis Comp Cancer Ctr /ID# 154644, Sacramento, California, United States
Yale University /ID# 136982, New Haven, Connecticut, United States
University of Chicago /ID# 155453, Chicago, Illinois, United States
Indiana Univ School Medicine /ID# 132946, Indianapolis, Indiana, United States
Duke Univ Med Ctr /ID# 154647, Durham, North Carolina, United States
Mary Crowley Cancer Research /ID# 154059, Dallas, Texas, United States
Univ TX, MD Anderson /ID# 132276, Houston, Texas, United States
UT MD Anderson Cancer Center /ID# 164122, Houston, Texas, United States
Contact Details
Name: AbbVie Inc.
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
